Eventide Asset Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Eventide Asset Management’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-317,417	Closed	-$41.8M	–	181
2020 Q4	$41.8M	Hold	317,417	–	–	0.64%	57
2020 Q3	$16M	Buy	317,417 +104,417	+49%	+$4.69M	0.31%	90
2020 Q2	$10.2M	Hold	213,000	–	–	0.22%	93
2020 Q1	$10.4M	Buy	+213,000	New	+$10.9M	0.34%	83
2018 Q3	–	Sell	-162,000	Closed	-$3.29M	–	153
2018 Q2	$3.29M	Buy	+162,000	New	+$3.4M	0.14%	100

Eventide Asset Management's EIDX Position: Q1 2021 in Review

Eventide Asset Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 317,417 shares — an estimated $41.8M sold.

Eventide Asset Management first reported a position in EIDX in Q2 2018 and held it in 5 quarters. The position peaked at $41.8M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Eventide Asset Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Eventide Asset Management sold 317,417 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $41.8M.
Eventide Asset Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 5 quarters.
Eventide Asset Management's Eidos Therapeutics, Inc. Common Stock position peaked at $41.8M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Eventide Asset Management's 13F filing for Q1 2021, filed 14 May 2021.